The veterinary diagnostic imaging market is set to reach from US$ 1,931.5 Mn in 2017 to US$ 3,473.9 Mn by 2026 at a compound annual growth rate (CAGR) of 6.8% during the forecast period from 2018 to 2026. Veterinary diagnostic imaging is a non-invasive procedure which is employed to obtain medical images of animals suffering with acute and chronic diseases.
The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2033. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted.
The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2021 to 2029. According to the research findings presented by the World Health Organization (WHO), in 2021 cancer is responsible for the death of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer.
T-cell lymphoma treatment market accounted for a market value of US$ 1300.8 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2025 to 2033. Lymphoma is divided into two types Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphoma is segmented as B-cell lymphoma and T-cell lymphoma, B-cell lymphoma accounted nearly 85% of the lymphoma diagnoses and remaining 15% being T-cell lymphoma.
The photodynamic therapy market is set to grow at an impressive rate with a compounded annual growth rate (CAGR) of 5.7% during the forecast period from 2018 to 2026. As per the statistics provided by World Health Organization (WHO), currently 2 to 3 million non-melanoma and 132,000 melanoma skin cancer occurs throughout the globe annually.
The global immunocytokines market is growing significantly. In recent years monoclonal antibodies are being utilized to treat a wide array of cancer-related diseases. These monoclonal antibodies are mainly mono-specific encompassing similar immune cells which are copies of a single parent cell and are concentrated towards a definite cellular target. These antibodies due to its customizable environment, it can be used to only treat the tumor cells ineffective of the normal ones in the living body.
Interest in investing and developing in proton therapy has exponentially increased over the past few decades, including the clinical advantage of Bragg peak dose as against the conventional high-energy X-ray distribution of photons.
The fragment-based drug discovery (FBDD) market is expected to experience a CAGR of 11.7% during the forecast period of 2025 to 2033, driven by several key drivers that have revolutionized drug development methodologies. FBDD is a robust and innovative approach that has gained prominence in the pharmaceutical industry due to its ability to identify highly potent lead compounds with lower molecular weight, ultimately simplifying the chemical synthesis and optimization process.
Hypothyroidism as a syndrome was first recognized in the 1870s and its treatment with animal extracted thyroid was achieved in 1890s. Since 1927, synthetic thyroid hormone replacement therapy has been available, and in the recent years, there has been a minor shift in treatment away from levothyroxine. The currently popular treatment forms include use of liothyronine T3 as a monotherapy or even commonly combined with levothyroxine T3/T4. However, there is not current formulation of T3/T4 that completely replicates the natural hormone pattern released from human thyroid.
The circulating tumor cells prognostic technologies market is set to reach US$ 22.7 billion by 2029 from US$ 3.4 billion in 2019. The market is expected to expand at an impressive growth rate of 21% during the forecast period of 2021 to 2029. The lockdown due to the spread of covid 19 contained the movement of people and access to healthcare institutes except in case of emergency.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.